Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. In addition to the highest-quality reviews and perspectives covering a broad scope, each issue includes news stories that investigate the hottest topics in drug discovery, timely summaries of key primary research papers, and concise updates on the latest advances in areas such as new drug approvals, patent law and emerging industry trends and strategies.
《自然评论药物发现》是一本月刊，面向所有在药物发现和开发竞技场工作的人。除了涵盖广泛范围的最高质量的综述和观点外，每期还包括调查药物发现中最热门话题的新闻报道、关键主要研究论文的及时摘要，以及新药批准、专利法和新兴行业趋势和战略等领域最新进展的简要更新。
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-018-0007-y
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-018-0008-x
The current state and future directions of RNAi-based therapeutics
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-019-0017-4
Adeno-associated virus vector as a platform for gene therapy delivery
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-019-0012-9
2018 FDA drug approvals
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00014-x
AMP-activated protein kinase: the current landscape for drug development
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-019-0019-2
Rethinking drug design in the artificial intelligence era
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-019-0050-3
Targeting metabolism to regulate immune responses in autoimmunity and cancer
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-019-0032-5
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-019-0035-2
Antibodies and venom peptides: new modalities for ion channels
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-019-0013-8
Targeting metabolic dysregulation for fibrosis therapy
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-019-0040-5
The global pipeline of cell therapies for cancer
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00090-z
Trends in clinical development for PD-1/PD-L1 inhibitors
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00182-w
Nav1.7 withholds its pain potential
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00065-0
Anticancer autophagy inhibitors attract ‘resurgent’ interest
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00072-1
Zebrafish earn their drug discovery stripes
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00165-x
Microbiome therapeutics go small molecule
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00122-8
Chemical inhibitors make their RNA epigenetic mark
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00179-5
Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00088-7
Pioneering antisense drug heads into pivotal trials for Huntington disease
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00018-7
Added therapeutic benefit and drug licensing
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00068-x
Massive NIH–industry project opens portals to target validation
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00033-8
The multiple myeloma drug market
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00031-w
Defining orphan conditions in the context of the European orphan regulation: challenges and evolution
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/nrd.2018.128
Biopharma dealmaking in 2018
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00013-y
Publisher Correction: The current state and future directions of RNAi-based therapeutics
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-019-0023-6
ADCK3/COQ8A: the choice target of the UbiB protein kinase-like family
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00158-w
The BCMA bonanza
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00105-9
Author Correction: Adaptive platform trials: definition, design, conduct and reporting considerations
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/s41573-019-0045-0
The FNIH Biomarkers Consortium embraces the BEST
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00015-w
FDA approves SMA gene therapy
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00101-z
Dumping STAT3 in the trash
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00197-3
Phages fight alcoholic hepatitis
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00198-2
Developing closed-loop neuromodulatory devices
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00011-0
Unlocking the power of translational medicine
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00030-x
Reshma Kewalramani
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00194-6
The acute myeloid leukaemia market
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00142-4
A stem-cell-derived eye patch for macular degeneration
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00017-8
Novel incretin receptor antibodies combat weight gain
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00008-9
Lowering mutant huntingtin protein
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00207-4
Treg conversion dampens autoimmunity
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00191-9
Decoy receptor targets lung cancer
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00206-5
GPR146 inhibition protects against atherosclerosis
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00204-7
Learning from worms to kill Gram-negative bacteria
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00208-3
A multipronged attack on malaria
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00163-z
Double boost for mRNA cancer vaccines
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00192-8
Harnessing venture philanthropy to accelerate medical progress
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00129-1
Roger Perlmutter
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00173-x
Jessica Mega
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00132-6
Daria Hazuda
来源期刊：Nature Reviews Drug DiscoveryDOI：10.1038/d41573-019-00091-y
